155 related articles for article (PubMed ID: 36372832)
1. Erythroblastic oncogene B-2 status and intracranial metastatic disease in patients with gastrointestinal cancer: a systematic review.
Sherman M; Gaebe K; Li AY; Habbous S; Sahgal A; Raphael MJ; Erickson AW; Das S
J Neurooncol; 2022 Dec; 160(3):735-742. PubMed ID: 36372832
[TBL] [Abstract][Full Text] [Related]
2. Enrichment of
Mitra D; Clark JW; Shih HA; Oh KS; Brastianos PK; Wo JY; Strickland MR; Curry WT; Parikh AR; Corcoran RB; Ryan DP; Iafrate AJ; Borger DR; Lennerz JK; Hong TS
Oncologist; 2019 Feb; 24(2):193-201. PubMed ID: 30373904
[TBL] [Abstract][Full Text] [Related]
3. Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease.
Erickson AW; Habbous S; Wright F; Lofters AK; Jerzak KJ; Das S
JAMA Oncol; 2021 Aug; 7(8):1220-1224. PubMed ID: 34081080
[TBL] [Abstract][Full Text] [Related]
4. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.
El Dika I; Ilson DH
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1085-1092. PubMed ID: 30092682
[TBL] [Abstract][Full Text] [Related]
5. Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.
Offin M; Feldman D; Ni A; Myers ML; Lai WV; Pentsova E; Boire A; Daras M; Jordan EJ; Solit DB; Arcila ME; Jones DR; Isbell JM; Beal K; Young RJ; Rudin CM; Riely GJ; Drilon A; Tabar V; DeAngelis LM; Yu HA; Kris MG; Li BT
Cancer; 2019 Dec; 125(24):4380-4387. PubMed ID: 31469421
[TBL] [Abstract][Full Text] [Related]
6. ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas.
Arrington AK; Dahlberg PS; Davydova J; Vickers SM; Yamamoto M
Surgery; 2009 Aug; 146(2):213-9. PubMed ID: 19628076
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis.
Gaebe K; Li AY; Park A; Parmar A; Lok BH; Sahgal A; Chan KKW; Erickson AW; Das S
Lancet Oncol; 2022 Jul; 23(7):931-939. PubMed ID: 35644163
[TBL] [Abstract][Full Text] [Related]
8. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal cancer and brain metastasis: a rare and ominous sign.
Go PH; Klaassen Z; Meadows MC; Chamberlain RS
Cancer; 2011 Aug; 117(16):3630-40. PubMed ID: 21319152
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.
de Calbiac O; Lusque A; Mailliez A; Bachelot T; Uwer L; Mouret-Reynier MA; Emile G; Jouannaud C; Gonçalves A; Patsouris A; Diéras V; Leheurteur M; Petit T; Cottu P; Ferrero JM; D'Hondt V; Desmoulins I; Mourato-Ribeiro J; Martin AL; Frenel JS
JAMA Netw Open; 2022 Sep; 5(9):e2231170. PubMed ID: 36107428
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
12. Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.
Blanco-Gómez A; Hontecillas-Prieto L; Corchado-Cobos R; García-Sancha N; Salvador N; Castellanos-Martín A; Sáez-Freire MDM; Mendiburu-Eliçabe M; Alonso-López D; De Las Rivas J; Lorente M; García-Casas A; Del Carmen S; Abad-Hernández MDM; Cruz-Hernández JJ; Rodríguez-Sánchez CA; Claros-Ampuero J; García-Cenador B; García-Criado J; Orimo A; Gridley T; Pérez-Losada J; Castillo-Lluva S
Cancer Res; 2020 Dec; 80(23):5216-5230. PubMed ID: 33023950
[TBL] [Abstract][Full Text] [Related]
13. Brain metastasis in gastroesophageal adenocarcinoma and HER2 status.
Limon D; Gal O; Gordon N; Katz L; Perl G; Purim O; Amit L; Stemmer SM; Kundel Y; Ben-Aharon I; Brenner B; Siegal T; Yust-Katz S
J Neurooncol; 2018 Jun; 138(2):315-320. PubMed ID: 29429124
[TBL] [Abstract][Full Text] [Related]
14. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
15. Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.
LeNoue-Newton ML; Chen SC; Stricker T; Hyman DM; Blauvelt N; Bedard PL; Meric-Bernstam F; Punglia RS; Schrag D; Lepisto EM; Andre F; Smyth L; Dogan S; Yu C; Wathoo C; Levy M; Eli LD; Xu F; Mann G; Lalani AS; Ye F; Micheel CM; Arnedos M
Clin Cancer Res; 2022 May; 28(10):2118-2130. PubMed ID: 35190802
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression.
Sutcliffe P; Connock M; Shyangdan D; Court R; Kandala NB; Clarke A
Health Technol Assess; 2013 Sep; 17(42):1-274. PubMed ID: 24070110
[TBL] [Abstract][Full Text] [Related]
17. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK
Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395
[TBL] [Abstract][Full Text] [Related]
18. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.
Paulson AK; Linklater ES; Berghuis BD; App CA; Oostendorp LD; Paulson JE; Pettinga JE; Melnik MK; Vande Woude GF; Graveel CR
Mol Cancer Res; 2013 Sep; 11(9):1112-21. PubMed ID: 23825050
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
[TBL] [Abstract][Full Text] [Related]
20. Patients undergoing surgery of intracranial metastases have different outcomes based on their primary pathology.
Chaichana KL; Gadkaree S; Rao K; Link T; Rigamonti D; Purtell M; Browner I; Weingart J; Olivi A; Gallia G; Bettegowda C; Brem H; Lim M; Quinones-Hinojosa A
Neurol Res; 2013 Dec; 35(10):1059-69. PubMed ID: 24070329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
